- Home
- QNCX vs ADVM Comparison
QNCX vs ADVM Comparison
Compare QNCX & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- ADVM
- Stock Information
- Founded
- QNCX 2012
- ADVM 2006
- Country
- QNCX United States
- ADVM United States
- Employees
- QNCX N/A
- ADVM N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QNCX Health Care
- ADVM Health Care
- Exchange
- QNCX Nasdaq
- ADVM Nasdaq
- Market Cap
- QNCX 47.7M
- ADVM 47.4M
- IPO Year
- QNCX 2019
- ADVM 2014
- Fundamental
- Price
- QNCX $1.64
- ADVM $2.39
- Analyst Decision
- QNCX Strong Buy
- ADVM Strong Buy
- Analyst Count
- QNCX 5
- ADVM 5
- Target Price
- QNCX $8.00
- ADVM $23.80
- AVG Volume (30 Days)
- QNCX 353.3K
- ADVM 338.5K
- Earning Date
- QNCX 08-12-2025
- ADVM 08-11-2025
- Dividend Yield
- QNCX N/A
- ADVM N/A
- EPS Growth
- QNCX N/A
- ADVM N/A
- EPS
- QNCX N/A
- ADVM N/A
- Revenue
- QNCX N/A
- ADVM $1,000,000.00
- Revenue This Year
- QNCX N/A
- ADVM N/A
- Revenue Next Year
- QNCX N/A
- ADVM $18.82
- P/E Ratio
- QNCX N/A
- ADVM N/A
- Revenue Growth
- QNCX N/A
- ADVM N/A
- 52 Week Low
- QNCX $0.51
- ADVM $1.78
- 52 Week High
- QNCX $2.45
- ADVM $10.14
- Technical
- Relative Strength Index (RSI)
- QNCX 64.95
- ADVM 44.19
- Support Level
- QNCX $1.48
- ADVM $2.11
- Resistance Level
- QNCX $1.68
- ADVM $2.60
- Average True Range (ATR)
- QNCX 0.14
- ADVM 0.22
- MACD
- QNCX 0.02
- ADVM -0.00
- Stochastic Oscillator
- QNCX 85.71
- ADVM 33.33
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.